Congress Boosts Neurostimulation Research Funding, Nexalin's DIFS Technology in Focus
Event summary
- Nexalin Technology participated in bipartisan Congressional initiatives supporting deep brain neurostimulation research, with provisions included in recent appropriations packages.
- H.R. 7091, introduced on January 15, 2026, aims to expand veterans' access to emerging treatments like Nexalin's DIFS technology.
- Nexalin's DIFS technology is currently being evaluated in a clinical study at UC San Diego with veterans from the San Diego VA community.
- Recent legislative actions include expanded support for neuromodulation research focused on stroke recovery and Alzheimer’s disease.
The big picture
The recent Congressional momentum supporting deep brain neurostimulation research underscores the growing recognition of non-invasive technologies like Nexalin's DIFS as potential breakthrough treatments for neurological and neuropsychiatric disorders. This legislative support aligns with Nexalin's strategic focus on addressing unmet medical needs in veterans and aging populations, positioning the company to capitalize on expanding research pathways and institutional interest in next-generation neurological therapies.
What we're watching
- Legislative Progress
- Whether H.R. 7091 will advance through the House Veterans Affairs Committee and become law, potentially expanding access to Nexalin's DIFS technology.
- Clinical Validation
- The pace at which Nexalin's ongoing clinical study at UC San Diego yields results, influencing broader adoption of its DIFS technology.
- Market Expansion
- How increased federal support for neuromodulation research will impact Nexalin's long-term growth strategy and market opportunities.
Related topics